ACT-1004

N/A

Report date: 2026/03/19 16:57:36

Base Information

Drug NameACT-1004
Drug Alias Nameanti-CD3/anti-CLDN18.2 bispecific T-cell engager (Accurus Biosciences)ACT-1004
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers
Mechanisms of ActionClaudin 18 protein modulatorsT cell surface glycoprotein CD3 modulators
TargetsClaudin-18 splice variant 2T cell surface glycoprotein CD3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAccurus Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesAccurus Biosciences Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A